ArticleOpen forum infectious diseases2018
Evaluation of Tuberculosis Treatment Response With Serial C-Reactive Protein Measurements.
Article in Open forum infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- C-reactive protein as a predictor of mortality in tuberculosis: systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Screening performance of C-reactive protein for active pulmonary tuberculosis in HIV-positive patients: A systematic review with a meta-analysis.Frontiers in immunology · 2022Pooled it
- Temporal Associations Among Body Mass Index, Fasting Insulin, and Systemic Inflammation: A Systematic Review and Meta-analysis.JAMA network open · 2021Pooled it
- Prognostic Performance of C-Reactive Protein for Tuberculosis Outcome: Protocol for a Systematic Review and Meta-Analysis.JMIR research protocols · 2026Article
- Future Prospects for Using Clinical Phenotypes in Tuberculosis Precision Medicine-An Approach for Clinical Management.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Review
- Evaluation of non-sputum-based diagnostics for pediatric tuberculosis: the Pediatric TB Diagnostic (PDTBDx) cohort protocol.medRxiv : the preprint server for health sciences · 2026Article
- C-Reactive Protein for Pulmonary Tuberculosis Screening and Treatment Response Monitoring in Children.Open forum infectious diseases · 2026Article
- Systemic Host Proteomic Signatures as Dynamic Markers for Monitoring Pulmonary Tuberculosis Treatment Response.Infection and drug resistance · 2026Review
- Assessment of some hematological and inflammatory parameters among patients with active pulmonary tuberculosis in Ibb governorate, Yemen.BMC infectious diseases · 2025Article
- Physiologic-Inflammatory-Nutrition (TRIAD-TB) Score at 72 Hours Predicts 30-Day Mortality and Length of Stay in Pulmonary Tuberculosis: A Prospective Cohort Study.Biomedicines · 2025Article
- The Halo Vest Immobilization for Craniocervical Junction Tuberculosis: A Comparison of Treatment Options.Orthopaedic surgery · 2025Article
- Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials.Frontiers in antibiotics · 2025Review
- Development of a clinical prediction model for poor treatment outcomes in the intensive phase in patients with initial treatment of pulmonary tuberculosis.Frontiers in medicine · 2025Article
- Blood and urine early treatment response biomarkers in HIV-associated disseminated tuberculosis.Southern African journal of HIV medicine · 2025Article
- Identification of Factors Determining Patterns of Serum C-Reactive Protein Level Reduction in Response to Treatment Initiation in Patients with Drug-Susceptible Pulmonary Tuberculosis.Antibiotics (Basel, Switzerland) · 2024Article
- The effect of Mycobacterium tuberculosis treatment on thrombelastography-assessed haemostasis: a prospective cohort study.Thrombosis journal · 2024Article
- C-reactive protein and procalcitonin use in adults in low- and middle-income countries: a narrative review.JAC-antimicrobial resistance · 2023Review
- Cardiovascular Involvement in Tuberculosis: From Pathophysiology to Diagnosis and Complications-A Narrative Review.Diagnostics (Basel, Switzerland) · 2023Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundNovel biomarkers are needed to assess response to antituberculosis therapy in smear-negative patients.
methodsTo evaluate the utility of C-reactive protein (CRP) in monitoring response to antituberculosis therapy, we conducted a post hoc analysis on a cohort of adults with symptoms of tuberculosis and negative sputum smears in a high-tuberculosis and HIV prevalence setting in KwaZulu-Natal, South Africa. Serial changes in CRP, weight, and hemoglobin were evaluated over 8 weeks.
resultsFour hundred twenty-one participants being evaluated for smear-negative tuberculosis were enrolled, and 33 were excluded. Two hundred ninety-five were treated for tuberculosis (137 confirmed, 158 possible), and 93 did not have tuberculosis. One hundred and eighty-three of 213 (86%) participants who agreed to HIV testing were HIV positive. At week 8, the on-treatment median CRP reduction in the tuberculosis group (interquartile range [IQR]) was 79.5% (25.4% to 91.7%), the median weight gain was 2.3% (-1.0% to 5.6%), and the median hemoglobin increase was 7.0% (0.8% to 18.9%);
conclusionsChange in CRP may have utility in early evaluation of response to antituberculosis treatment and to identify those at increased risk of adverse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.